[{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATG-019","moa":"PAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Series C Financing","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Antengene \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Antengene","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATG-017","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ AstraZeneca"},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ WuXi Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Antengene \/ WuXi Biologics"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Eltanexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"oral","sponsorNew":"Antengene \/ Karyopharm Therapeutic","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Karyopharm Therapeutic"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase III","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"ATG-022","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Antengene","highestDevelopmentStatusID":"4","companyTruncated":"Antengene \/ Antengene"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Onatasertib","moa":"mTORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Preclinical","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Calithera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CB-708","moa":"CD73","graph1":"Oncology","graph2":"Preclinical","graph3":"Antengene","amount2":0.26000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"Oral","sponsorNew":"Antengene \/ Antengene","highestDevelopmentStatusID":"4","companyTruncated":"Antengene \/ Antengene"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Onatasertib","moa":"mTORC1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ATG-037","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Karyopharm","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Karyopharm"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Onatasertib","moa":"TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ATG-018","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1 inhibitor\/4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ATG-017","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ATG-031","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ATG-022","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Antengene \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Hansoh Pharma"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ATG-031","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ATG-022","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ATG-031","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Antengene
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
